Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Inclusion criteria

• ✓. Patient\* has given written informed consent.
• ✓. Patient is ≥ 18 years of age at time of signing the written informed consent.
• ✓. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
• ✓. Patient has been diagnosed with histologically or cytologically confirmed
• ✓. histologically or cytologically confirmed cholangiocarcinoma as adenocarcinoma of pancreatobiliary type
• ✓. unresectable perihilar and/or ductal cholangiocarcinoma with indication for bile duct stenting and palliative systemic therapy as determined by the local multidisciplinary team (MDT) and already resolved cholestasis due to RFA + stent
• ✓. Patient tolerated RFA prior to inclusion and is eligible for repeat RFA during the study (does not have any contraindications) as determined by investigator.
• ✓. Patient is eligible for palliative systemic therapy based on clinical and laboratory parameters (except hyperbilirubinemia) as determined by the local MDT

Exclusion criteria